SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addit...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/9032378 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560928822919168 |
|---|---|
| author | Luis D'Marco Valery Morillo José Luis Gorriz María K. Suarez Manuel Nava Ángel Ortega Heliana Parra Nelson Villasmil Joselyn Rojas-Quintero Valmore Bermúdez |
| author_facet | Luis D'Marco Valery Morillo José Luis Gorriz María K. Suarez Manuel Nava Ángel Ortega Heliana Parra Nelson Villasmil Joselyn Rojas-Quintero Valmore Bermúdez |
| author_sort | Luis D'Marco |
| collection | DOAJ |
| description | Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in proinflammatory cytokines and with an improvement in the inflammatory profile in chronic endocrine-metabolic diseases. Hence, these drugs have been positioned as first-line therapy in the management of diabetes and its multiple comorbidities, such as obesity, which has been associated with persistent inflammatory states that induce dysfunction of the adipose tissue. Moreover, other frequent comorbidities in long-standing diabetic patients are chronic complications such as diabetic kidney disease, whose progression can be slowed by SGLT2i and/or GLP-1RA. The neuroendocrine and immunometabolism mechanisms underlying adipose tissue inflammation in individuals with diabetes and cardiometabolic and renal diseases are complex and not fully understood. Summary. This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise. |
| format | Article |
| id | doaj-art-2429d38f9c04442fa80e1693aa5bb47e |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-2429d38f9c04442fa80e1693aa5bb47e2025-02-03T01:26:24ZengWileyJournal of Diabetes Research2314-67532021-01-01202110.1155/2021/9032378SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and SenescenceLuis D'Marco0Valery Morillo1José Luis Gorriz2María K. Suarez3Manuel Nava4Ángel Ortega5Heliana Parra6Nelson Villasmil7Joselyn Rojas-Quintero8Valmore Bermúdez9Hospital Clínico Universitario de ValenciaEndocrine and Metabolic Diseases Research CenterHospital Clínico Universitario de ValenciaEndocrine and Metabolic Diseases Research CenterEndocrine and Metabolic Diseases Research CenterEndocrine and Metabolic Diseases Research CenterEndocrine and Metabolic Diseases Research CenterSchool of MedicineDivision of Pulmonary and Critical Care MedicineUniversidad Simón BolívarBackground. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in proinflammatory cytokines and with an improvement in the inflammatory profile in chronic endocrine-metabolic diseases. Hence, these drugs have been positioned as first-line therapy in the management of diabetes and its multiple comorbidities, such as obesity, which has been associated with persistent inflammatory states that induce dysfunction of the adipose tissue. Moreover, other frequent comorbidities in long-standing diabetic patients are chronic complications such as diabetic kidney disease, whose progression can be slowed by SGLT2i and/or GLP-1RA. The neuroendocrine and immunometabolism mechanisms underlying adipose tissue inflammation in individuals with diabetes and cardiometabolic and renal diseases are complex and not fully understood. Summary. This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise.http://dx.doi.org/10.1155/2021/9032378 |
| spellingShingle | Luis D'Marco Valery Morillo José Luis Gorriz María K. Suarez Manuel Nava Ángel Ortega Heliana Parra Nelson Villasmil Joselyn Rojas-Quintero Valmore Bermúdez SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence Journal of Diabetes Research |
| title | SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence |
| title_full | SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence |
| title_fullStr | SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence |
| title_full_unstemmed | SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence |
| title_short | SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence |
| title_sort | sglt2i and glp 1ra in cardiometabolic and renal diseases from glycemic control to adipose tissue inflammation and senescence |
| url | http://dx.doi.org/10.1155/2021/9032378 |
| work_keys_str_mv | AT luisdmarco sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT valerymorillo sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT joseluisgorriz sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT mariaksuarez sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT manuelnava sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT angelortega sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT helianaparra sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT nelsonvillasmil sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT joselynrojasquintero sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence AT valmorebermudez sglt2iandglp1raincardiometabolicandrenaldiseasesfromglycemiccontroltoadiposetissueinflammationandsenescence |